NOK 138.90
+2.90 (+2.13%)
NOK · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DOFG.OL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 observational
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast ReconstructionNCT06555614observationalIncidence Rate(%) of Major Short-Term Complications Over 12 Weeks Post-Application of ADM | — | Recruiting | Other: Acellular Dermal Matrix(ADM) | Breast Cancer Female, Breast Reconstruction | 120 | 2026-12-31 | in 133 d | 2026-04-28 |
| Evaluation of the Clinical Effectiveness and Safety of Acellular Dermal Matrix(SC DERM® Recon) in Breast ReconstructionNCT06555692observationalAssessment of Breasts by Independent Investigator Using a 5-Point Likert Scale | — | Active, not recruiting | Biological: Transplant acellular dermal matrix(ADM) | Breast Cancer Female, Breast Reconstruction | 120 | 2026-06-30 | — | 2026-04-28 |
| Evaluation of ADM(SC Derm® Recon) in Breast ReconstructionNCT06553859observationalThe number of occurrences of pre-determined expected adverse events and complications | — | Unknown status | Other: No intervention conducts. | Breast Cancer Female | 100 | Jun 2025 | — | 2024-08-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19